

RECEIVED
PATENT

DEC 15 2006

IN THE CLAIMS:

TECH CENTER 1606.1.100

Please delete claim 3.Please amend claims 1, 4, 6, 7, 19, and 20 as follows:

1. (Twice Amended) A neuronal cell line obtained from a transgenic rat, the cells of which comprise: [comprising:]

(i) a conditional oncogene, transforming gene or immortalizing gene or a cell cycle affecting gene operably linked to

(ii) a cell type specific promoter.

4. (Twice Amended) [A] The cell line [as claimed in claim 3] of claim 1 in which the cell type specific promoter is a human NF-L gene promoter.

6. (Twice Amended) [A] The cell line [as claimed in any of claims 1, 3,] of claim 1 or 4 in which the conditional oncogene, transforming gene or immortalizing gene or the cell cycle affecting gene is a SV40tsA58 gene.

7. (Twice Amended) [A] The cell line [as claimed in any of claims 1, 3,] of claim 1 or 4 in which the conditional oncogene, transforming gene, immortalising gene or the cell cycle affecting gene is a C Erb β 2 gene or a TGF α gene.

19. (Twice Amended) A method of testing a material suspected of being a carcinogen, said method comprising subjecting a rat according to claim 17 or 18 [or a rat produced according to the method of any of claims 13 or 15 or an ancestor thereof or cells or tissue from a cell line of any of claims 1, 3, 4, 6, 7, 8, or 9,] to said material and detecting neoplasms as an indication of carcinogenicity.

PATENT
RECEIVED

DEC 15 2006

TECH CENTER 1600

20. (Twice Amended) A method of testing a material suspected of conferring protection against the development of neoplasms, said method comprising administering said material to a rat according to claim 17 or 18 [or a rat produced according to a method of claims 13 or 15 or an ancestor thereof or cells or tissues from a cell line of any of claims 1, 3, 4, 6, 7, 8, or 9,] and detecting a reduced incidence of development or neoplasms, compared to an untreated rat, as an indication of said protection.

Please add the following claims 30-32:

--30. The method of claim 13 wherein the conditional oncogene, transforming gene or immortalizing gene or the cell cycle affecting gene is a SV40tsA58 gene, a C Erb β 2 gene or a TGF α gene and wherein the cell type specific promoter is a human NF-L gene promoter.

31. The transgenic rat of claim 18 wherein the cell type specific promoter is a human NF-L gene promoter.

32. The method of claim 25 wherein the conditional oncogene, transforming gene or immortalizing gene or the cell cycle affecting gene is a SV40tsA58 gene, a C Erb β 2 gene or a TGF α gene and wherein the cell type specific promoter is a human NF-L gene promoter.--